Loading
Repackaging two old chemotherapies into liposomes doubled five-year survival in older adults with the worst kinds of AML.
CPX-351 Study 301, trial NCT01696084 sponsored by Celator, now Jazz, and published in JCO in 2018 with a five-year update in Lancet Haematology in 2021, showed that repackaging daunorubicin and cytarabine into liposomes doubled five-year survival in adults aged 60 to 75 with newly diagnosed high-risk or secondary acute myeloid leukaemia. It randomised 309 patients to CPX-351 or conventional 7+3 chemotherapy, met its primary overall survival endpoint, raised the remission rate, and more patients reached transplant with longer survival afterwards. OnCo links it to acute myeloid leukaemia, the CPX-351 record and the 7+3 regimen. There is no second randomised trial, although the UK NCRI AML19 trial and real-world registries report comparable remission rates in secondary disease, and whether the benefit holds in younger patients or against venetoclax-based regimens is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
309 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival (median)primary | CPX-351 | 153 | 9.56 months | 0.69 (0.52 to 0.9) | 0.003 | link |
| 7+3 | 156 | 5.95 months | ||||
| 5-year overall survival | CPX-351 | - | 18% | - | - | link |
| 7+3 | - | 8% |
Shares Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia.
Shares CPX-351 (liposomal daunorubicin-cytarabine), Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Cytarabine + anthracycline ('7+3'), Acute myeloid leukaemia.
Shares Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Cytarabine + anthracycline ('7+3'), Acute myeloid leukaemia.